Evidence map›Paper›PMID 33364224›Full record

ReviewFrontiers in public health2020

Multilevel Engagements of Pharmacists During the COVID-19 Pandemic: The Way Forward.

Tauqeer Hussain Mallhi, Aroosa Liaqat, Arooj Abid, Yusra Habib Khan, Nasser Hadal Alotaibi, Abdulaziz Ibrahim Alzarea, Nida Tanveer, Tahir Mehmood Khan

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. COVID-19 vaccination in high-risk communities: Case study of Brampton, Ontario.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Telepharmacy during COVID-19: A Scoping Review.Pharmacy (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Tauqeer Hussain MallhiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Aroosa LiaqatPunjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
Arooj AbidPrimary and Secondary Healthcare Department, Tehsil Headquarter Hospital, Rawalpindi, Pakistan.
Yusra Habib KhanDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Nasser Hadal AlotaibiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Abdulaziz Ibrahim AlzareaDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Nida TanveerTehsil Headquarter Hospital, Jaranwala, Faisalabad, Pakistan.
Tahir Mehmood KhanInstitute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.
Al Jouf University · SAUniversity of the Punjab · PKUniversity of Veterinary and Animal Sciences · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) was first reported in China in December 2019 which was later declared to be a public health emergency of international concern by the World Health Organization (WHO). This virus proved to be very contagious resulting in life-threatening respiratory intricacies posing overall public health and governance challenges. Amid the coronavirus pandemic and the unprecedented increase in healthcare demands, only inventive and adaptive practice among healthcare professionals is the need of the hour. Pharmacy services are an important mainstay in the public health and have considerable potential to combat the coronavirus disease 2019 (COVID-19) pandemic. Pharmacists working in several localities and health facilities are linked to patients either directly or indirectly. They can act swiftly in public health response such as drafting professional service guidance to pharmacists working in various healthcare facilities, ensuring effective medicine supply system, monitoring and resolving drug shortage issues, establishing and promoting remote pharmacy services, counseling the public on infection prevention basics, educating about proper use of personal protective equipment, discouraging self-medication, participating in clinical trials, small-scale manufacturing of sanitizers and disinfectants, busting the prevailing myths, and conducting drug evaluation and active surveillance. These interventions will help ease unprecedented burden on healthcare facilities during the ongoing pandemic and eventually will add value to patients and the healthcare system. The current manuscript accentuates the potential roles and activities that pharmacists can initiate in various healthcare facilities to help in relieving pressure on the overwhelmed healthcare system. The information and suggestions offered in this review could help in the restructuring of existing pharmacy services by governments, public health bodies, and policy makers in response to the COVID-19 pandemic. Moreover, this manuscript will underscore any unrealized potential among pharmacists working in various sectors including community, hospital, industry, and drug regulatory authorities.

Indexed as

Professional RolePublic HealthChinaCOVID-19Delivery of Health CareHumansPharmacistsSARS-CoV-2clinical pharmacistcommunity pharmacistcoronavirusCOVID-19industrial pharmacistpandemicpharmacistpharmacy services

Identifiers

PMID33364224
PMCPMC7753011
OpenAlexW3111971814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.